<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148287</url>
  </required_header>
  <id_info>
    <org_study_id>APX001-203</org_study_id>
    <nct_id>NCT04148287</nct_id>
  </id_info>
  <brief_title>An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris</brief_title>
  <acronym>APEX</acronym>
  <official_title>An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and/or Invasive Candidiasis Caused by Candida Auris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of&#xD;
      APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in&#xD;
      patients aged 18 years and over with limited antifungal treatment options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, non-comparative, single arm study to evaluate the efficacy&#xD;
      and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C.&#xD;
      auris in patients aged 18 years and over with limited antifungal treatment options. The Study&#xD;
      Drug Treatment Period will be up to a maximum of 42 days (inclusive of the loading dose&#xD;
      [Study Day 1]). There will be a Follow up Period of 4 weeks (+4 days) after EOST. The total&#xD;
      duration of participation in the study is up to approximately 10.5 weeks (inclusive of the&#xD;
      Screening Period [168 hours prior to Baseline]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was closed early as the result of the impact of COVID-19 on trial-related activities.&#xD;
    The study was not terminated due to any safety issues or concerns. The objectives of the study&#xD;
    were successfully met.&#xD;
  </why_stopped>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single arm intervention. All patients will receive APX001. On Days 1-3, APX001 will be administered intravenously. Thereafter, if the patient is able to take oral medication, APX001 tablets will be taken orally.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>The primary efficacy parameter is percentage of patients with Treatment Success at end of study treatment as determined by the Data Review Committee (DRC).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Candidemia</condition>
  <condition>Invasive Candidiases</condition>
  <condition>Candida Infection</condition>
  <arm_group>
    <arm_group_label>APX001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APX001 IV or oral for up to 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001</intervention_name>
    <description>Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.</description>
    <arm_group_label>APX001</arm_group_label>
    <other_name>fosmanogepix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Limited or no treatment options due to resistance, contraindication, intolerance or&#xD;
             lack of clinical response to standard of care antifungal therapy, as advocated by the&#xD;
             relevant regional/country treatment guidelines&#xD;
&#xD;
          -  Established mycological and clinical diagnosis of candidemia and/or invasive&#xD;
             candidiasis caused by Candida auris&#xD;
&#xD;
          -  Able to have pre-existing intravascular catheters removed and replaced (if necessary)&#xD;
&#xD;
          -  Females of childbearing potential with male partners, and males with female partner(s)&#xD;
             of childbearing potential, must agree to use 2 forms of highly effective contraception&#xD;
             throughout the duration of the study and for 90 days following the last study drug&#xD;
             administration. Females of childbearing potential must have a negative urine pregnancy&#xD;
             test within 96 hours prior study entry.&#xD;
&#xD;
          -  Wiling to participate in the study, willing to give written informed consent, and&#xD;
             willing to comply with the study restrictions; where permitted by local regulations,&#xD;
             written informed consent from a legal authorized representative (LAR) will be obtained&#xD;
             for patients who are unable to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than 7 days in the opinion of the Investigator&#xD;
&#xD;
          -  Human immunodeficiency virus-infected patients who are receiving antiretroviral&#xD;
             therapy that are moderate to strong inducers of CYP3A4, or who have detectable&#xD;
             viremia, or who have had an active opportunistic infection within 6 months prior&#xD;
&#xD;
          -  Alanine aminotransferase or aspartate aminotransferase greater than or equal to 5&#xD;
             times the upper limit of normal&#xD;
&#xD;
          -  Total bilirubin greater than 3 time the upper limit of normal, unless isolated&#xD;
             hyperbilirubinemia or due to documented Gilbert's disease&#xD;
&#xD;
          -  Pregnant or lactating female patient&#xD;
&#xD;
          -  Inappropriate fungal infection source control&#xD;
&#xD;
          -  Investigational drug administered within 30 days prior to dosing or five half-lives&#xD;
             whichever is longer&#xD;
&#xD;
          -  Diagnosis of deep-seated Candida-related infections causing hardware associated septic&#xD;
             arthritis, osteomyelitis, endocarditis, myocarditis, hepatosplenic candidiasis, or a&#xD;
             central nervous system infection or site of infection that would require antifungal&#xD;
             therapy to exceed the maximal duration of study drug treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidemia</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared in a manuscript. All IPD will be anonymized. IPD will include summarized efficacy, safety and pharmacokinetics data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Approximately 6 months following the last patient's last visit in the study.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04148287/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04148287/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

